INmune Bio Inc.

Stage 3 · Topping · week 1

As of Oct 22, 2026, INmune Bio is in Stage 3, the topping phase, now in its first week (since Oct 20, 2026). It closed at $1.54, 38.6% below its 52-week high and below its 200-day average, which is falling.

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. More about the company

$1.54

-4.35% today

$42.7M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is INMB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 16w

S4 30w

S4 31w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 2w → S3 4w → S4 9w → S1 2w → S2 16w → S3 11w → S4 30w → S1 5w → S2 7w → S3 11w → S4 31w → S1 1w → S4 12w → S1 10w → S2 12w → S3 1w current

Total tracked: 165 weeks across 16 stage runs.

INMB among Biotechnology244th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…244	INMBINmune Bio Inc.	Stage 3 · wk 1	40	−23.0%

vs 52W High

-38.6%

$1.12 lo$2.51 hi

38.6% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 1

1w13w26w

Week 1, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-6.0%

200 DMA: $1.64 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.66x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-23.0%

-4.9%

+11.6%

YTD

+0.0%

-18.5%

Scan Membership

Breakout Watch

Latest: 2025-02-26

9 appearances in last 60 days. First seen: 2020-06-12.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 1 · Vol 0.66x

2026-10-21S3

Wk 1 · Vol 0.67x

2026-10-20S32→3

Wk 1 · Vol 0.22x

2026-10-19S2

Wk 12 · Vol 0.44x

2026-10-16S2

Wk 12 · Vol 0.55x

2026-10-15S2

Wk 12 · Vol 1.75x

2026-10-14S2

Wk 12 · Vol 3.32x

2026-10-13S2

Wk 12 · Vol 0.72x

2026-10-12S2

Wk 11 · Vol 0.21x

2026-10-09S2

Wk 11 · Vol 0.26x

2026-10-08S2

Wk 11 · Vol 1.11x

2026-10-07S2

Wk 11 · Vol 0.30x

Moving averages & range

50 DMA

$2.07

200 DMA

$1.64

52W High

$2.51

52W Low

$1.12

5D Low

$1.54

Resistance levels (recent highs)

20d High

$2.03

60d High

$2.51

120d High

$2.51

250d High

$2.51

Next resistance

+31.8%

to 20d High

ROE

-74.8%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.1

INmune Bio: quick answers

What stage is INmune Bio in?

As of Oct 22, 2026, INmune Bio (INMB) is in Stage 3, the topping phase. It entered Stage 3 on Oct 20, 2026 and is in its first week there. What the four stages mean

Is INmune Bio in an uptrend?

Its uptrend has stalled. INmune Bio is in Stage 3, the topping phase that follows an advance. It trades 6.0% below its 200-day average, which is falling.

How far is INmune Bio from its 52-week high?

INmune Bio closed at $1.54 on Oct 22, 2026, 38.6% below its 52-week high of $2.51. Its 52-week low is $1.12.

How has INmune Bio performed over the past year?

As of Oct 22, 2026, INmune Bio is down 18.5% over the past year and flat so far in 2026.

Which sector and industry is INmune Bio in?

INmune Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.